Can-Fite BioPharma Annual Meeting Adjourned Due to Lack of Quorum

Ticker: CANF · Form: 6-K · Filed: Jun 26, 2024 · CIK: 1536196

Can-Fite Biopharma LTD. 6-K Filing Summary
FieldDetail
CompanyCan-Fite Biopharma LTD. (CANF)
Form Type6-K
Filed DateJun 26, 2024
Risk Levelmedium
Pages1
Reading Time1 min
Sentimentneutral

Sentiment: neutral

Topics: meeting-adjournment, shareholder-meeting, quorum-issue

Related Tickers: CFBI

TL;DR

CFBI annual meeting pushed to July 3rd due to no quorum, major shareholder turnout needed.

AI Summary

Can-Fite BioPharma Ltd. announced that its Annual General Meeting of Shareholders, originally scheduled for June 26, 2024, was adjourned due to a lack of quorum. The meeting will now reconvene on Wednesday, July 3, 2024, at 3:00 p.m. Israel time at the company's offices in Ramat Gan, Israel.

Why It Matters

The adjournment of the annual meeting due to a lack of quorum may indicate shareholder disengagement or potential issues with corporate governance, which could impact future decision-making and investor confidence.

Risk Assessment

Risk Level: medium — Adjournment due to lack of quorum can signal underlying issues with shareholder participation or confidence, potentially impacting corporate actions and stock performance.

Key Numbers

Key Players & Entities

FAQ

Why was the Annual General Meeting adjourned?

The Annual General Meeting was adjourned due to a lack of quorum.

When will the Annual General Meeting reconvene?

The Annual General Meeting will reconvene on Wednesday, July 3, 2024.

What time is the reconvened meeting?

The reconvened meeting is scheduled for 3:00 p.m. Israel time.

Where will the reconvened meeting be held?

The reconvened meeting will be held at the Company's offices located at 26 Ben Gurion Street, Ramat Gan, Israel.

What is the company's exact name as specified in its charter?

The company's exact name is Can-Fite BioPharma Ltd.

Filing Stats: 215 words · 1 min read · ~1 pages · Grade level 11.8 · Accepted 2024-06-26 16:15:02

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: June 26, 2024 By: /s/ Motti Farbstein Motti Farbstein Chief Executive Officer and Chief Financial Officer 2

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing